Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective randomized phase IV open label comparative study of dalteparin vs unfractionated heparin in high risk patients of non-ST elevation acute coronary syndromes intended for early invasive strategy.

Trial Profile

Prospective randomized phase IV open label comparative study of dalteparin vs unfractionated heparin in high risk patients of non-ST elevation acute coronary syndromes intended for early invasive strategy.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 14 Oct 2011

At a glance

  • Drugs Dalteparin sodium; Heparin
  • Indications Acute coronary syndromes; Embolism and thrombosis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 14 Oct 2011 Actual initiation date (Jun 2007) added as reported by ClinicalTrials.gov.
    • 10 Mar 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top